Alda Pharmaceuticals Corp (C:APH)
Shares Issued 43,997,799
Last Close 2/15/2008 $0.89
Tuesday February 19 2008 - News Release

Dr. Terrance Owen reports:

ALDA RECEIVES ISSUE NOTIFICATION FOR US PATENT

Vancouver, BC - ALDA Pharmaceuticals Corp. (APH:TSX-V, "ALDA") is pleased to announce that the United States Patent and Trademark Office ("USPTO") has provided ALDA with an "Issue Notification" stating that US Patent Application No. 10/525,110 is projected to be issued on March 4, 2008 as U.S. Patent No. 7,338,927. The patent provides protection for the composition and production methods for ALDA's T36trademark formulation.

Dr. Terrance Owen, President & CEO, states, "Receiving notification that the US patent will be issued very soon is the culmination of years of work and important validation of ALDA's technology. Clearly, patent protection in the United States is extremely important to ALDA and is a major asset that brings additional value to the company"

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection control therapeutics derived from its patented T36trademark technology. The company trades on the TSX Venture Exchange under the symbol APH.

Terrance G. Owen, Ph.D., MBA

President, CEO and Director

ALDA Pharmaceuticals Corp.